

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

~~A is a substituted moiety of up to 40 carbon atoms of the formula: $\text{L}(\text{M}-\text{L}^+)_q$, where L is a 5 or 6 membered cyclic structure bound directly to D, L^+ comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^+ contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and~~

~~B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6 member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein L^+ is substituted by at least one substituent selected from the group consisting of SO_2R_x , $\text{C}(\text{O})\text{R}_x$ and $\text{C}(\text{NR}_y)\text{R}_z$,~~

~~R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,~~

~~R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~R_x is R_z or NR_aR_b , where R_a and R_b are~~ a) ~~independently hydrogen,~~

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and~~

~~carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

~~-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~b) — R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~c) — one of R_a or R_b is C(O), a C₁-C₅ divalent alkylene group or a substituted C₁-C₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C₁-C₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~where B is substituted, L is substituted or L[†] is additionally substituted, the substituents are selected from the group consisting of halogen, up to per halo, and W_n, where n is 0-3;~~

~~wherein each W is independently selected from the group consisting of CN, CO₂R⁷, C(O)NR⁷R⁷, C(O)R⁷, NO₂, OR⁷, SR⁷, NR⁷R⁷, NR⁷C(O)OR⁷, NR⁷C(O)R⁷, Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of CN, CO₂R⁷, C(O)R⁷, C(O)NR⁷R⁷, OR⁷, SR⁷, NR⁷R⁷, NO₂, NR⁷C(O)R⁷, NR⁷C(O)OR⁷ and halogen up to per halo; with each R⁷ independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen;~~

wherein Q is ~~O, S, N(R⁷), (CH₂)_m, C(O), CH(OH), (CH₂)_mO, (CH₂)_mS,~~
~~(CH₂)_mN(R⁷), O(CH₂)_mCHX^a, CX^a₂, S(CH₂)_m and N(R⁷)(CH₂)_m, where m=1-3,~~
and X^a is halogen; and

~~Ar is a 5 or 6 member aromatic structure containing 0-2 members selected from the~~
~~group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen,~~
~~up to per halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is~~
~~independently selected from the group consisting of CN, CO₂R⁷, C(O)R⁷, C(O)NR⁷R⁷,~~
~~NO₂, OR⁷, SR⁷, NR⁷R⁷, NR⁷C(O)OR⁷, NR⁷C(O)R⁷, and a carbon-based moiety of up to~~
~~24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally~~
~~substituted by one or more substituents selected from the group consisting of CN, CO₂R⁷,~~
~~COR⁷, C(O)NR⁷R⁷, OR⁷, SR⁷, NO₂, NR⁷R⁷, NR⁷C(O)R⁷, and NR⁷C(O)OR⁷, with R⁷~~
~~as defined above.~~

A is a substituted moiety of the formula:



wherein L is a phenyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl,
isoxazolyl, isothiazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl or triazinyl,
and L is optionally substituted by halogen, up to per-halo, and W_n, where n is 0-3;

wherein each W is independently selected from the group consisting of C₁-C₅ linear
or branched alkyl, C₁-C₅ linear or branched haloalkyl up to perhalo, C₁-C₃ alkoxy, C₁-C₃
haloalkoxy up to per haloalkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino,
halogen, -CN, and -NO₂;

~~carbon-based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected~~
~~from N, S and O and optionally substituted by one or more substituents independently~~
~~selected from the group consisting of CN, CO₂R⁷, C(O)R⁷, C(O)NR⁷R⁷, OR⁷, SR⁷,~~
~~NR⁷R⁷, NO₂, NR⁷C(O)R⁷, NR⁷C(O)OR⁷ and halogen up to per halo;~~

~~with each R⁷ independently selected from H or a carbon-based moiety of up to 24 carbon~~
~~atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted~~
~~by halogen;~~

L¹ comprises a substituted cyclic moiety selected from the group consisting of:

(i) phenyl, naphthyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzoxazolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, indolyl, benzimidazolyl, benzopyrazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl and quinazolinyl,

optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'}, halogen, cyano and nitro;

wherein L¹ is substituted by -C(O)R_x,

wherein R_x is R_z or NR_aR_b and R_a and R_b are

A) independently

- a) hydrogen,
- b) C₁-C₁₀ alkyl,
- c) C₃₋₁₀ cycloalkyl, having 0-3 heteroatoms selected from N, S and O
- d) C₆ aryl,
- e) C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S,
- f) substituted C₁₋₁₀ alkyl,
- g) substituted C₃₋₁₀ cycloalkyl, having 0-3 heteroatoms selected from N, S and O,
- h) substituted C₆ aryl,
- i) substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O,
- j) -phenylpiperazine(pyridyl) or
- k) -C₂H₄NH(phenyl);

where R_a and R_b are a substituted group, they are substituted by

- a) halogen up to per halo,
- b) hydroxy,
- c) -N(CH₃)₂,
- d) C₁-C₁₀ alkyl,
- e) C₁-C₁₀ alkoxy,
- f) C₃₋₁₂ cycloalkyl, having 1-3 heteroatoms selected from O, N and S,

g) halosubstituted C₁₋₆ alkyl, or

h) -OSi(Pr-i)₃

B) R_a and R_b together form piperazine or a substituted piperazine
with substituents selected from the group consisting of

a) halogen,

b) hydroxy,

c) C₁₋₁₀ alkyl,

d) C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O,

f) C₁₋₁₀ alkoxy,

g) C₆ aryl,

h) halo substituted C₁₋₆ alkyl up to per halo alkyl,

i) halo substituted C₆ aryl up to per halo aryl,

j) N-(4-acetylphenyl);

k) halo substituted C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S
and O, up to per halo cycloalkyl, and

l) halo substituted C₃-C₁₂ hetaryl up to per halo heteraryl,

or

C) one of R_a or R_b is -C(O)- bound to the moiety L¹ to form an isoindoline-1, 3-
dione structure or a C₁ divalent alkylene group or a substituted C₁ divalent alkylene group
bound to the moiety L¹ to form a 1-oxo-isoindoline structure,

wherein the substituents of the substituted C₁ divalent alkylene group are selected from the
group consisting of

a) halogen,

b) hydroxy,

c) C₁₋₁₀ alkyl,

d) C₃₋₁₂ cycloalkyl having 0-3 heteroatoms selected from O, S and N,

e) C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O,


f) C₁₋₁₀ alkoxy,

g) C₆ aryl,

h) halo substituted C₁₋₆ alkyl up to per halo alkyl,

- i) halo substituted C₆aryl up to per halo aryl,
- j) halo substituted C₃-C₁₂ cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, and
- k) halo substituted C₃-C₁₂ hetaryl up to per halo heteroaryl;

M is selected from the group consisting of



where m and l are each independently integers of from 1-3, and X^a is halogen; and

B is selected from the group consisting of:

- (i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R⁷, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R⁷, NR⁷C(O)R⁷, NR⁷C(O)OR⁷, halogen, cyano, and nitro;
- (ii) naphthyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R⁷, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R⁷, NR⁷C(O)R⁷, NR⁷C(O)OR⁷, halogen, cyano, and nitro;
- (iii) pyridinyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R⁷, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R⁷, NR⁷C(O)R⁷, NR⁷C(O)OR⁷, halogen, cyano, and nitro; and

(iv) quinolinyl or isoquinolinyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R^7 , OR^7 , NR^7R'' , $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R''$, $NR^7C(O)R^7$, $NR^7C(O)OR^7$, halogen, cyano, and nitro;

each R^7 , R'' , R_z is independently

(a) hydrogen,

(b) C_1 - C_6 linear, branched, or cyclic alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy and hydroxy;

(c) C_1 - C_6 linear or branched, alkoxy, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy, hydroxy and halogen;

(d) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy, hydroxy and halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy, hydroxy and halogen,

(f) C_1 - C_3 alkyl-phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy, hydroxy and halogen; and

(g) up to per-halo substituted C_1 - C_5 linear, branched or cyclic alkyl, and where not per-halo substituted, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy and hydroxy.

2. (Canceled)

3. (Currently Amended) A compound as in claim 1 wherein M is one or more bridging groups selected from the group consisting of $-O-$, $-S-$, $N(R^7)-$, $-(CH_2)_m-$,

~~C(O)-, CH(OH)-, (CH₂)_mO-, (CH₂)_mS-, (CH₂)_mN(R⁷)-, O(CH₂)_m-, CHX^a-, CX^a₂-, S-~~
~~(CH₂) and N(R⁷)(CH₂)_m-, (CH₂)_m-, where m=1-3, X^a is halogen and~~
~~-O-, -S-, -N(R⁷)-, -C(O)-, -CH(OH)-, -(CH₂)O-, -(CH₂)S-, -(CH₂)N(R⁷)-, -O(CH₂)-, -CHF-,~~
~~-CF₂-, -S-(CH₂)- and -N(R⁷)(CH₂)-, -C(O)CH₂-, -CH₂OC(O)-, -C(O)OCH₂-,~~
~~-C(O)N(R⁷)CH₂-, -N(R⁷)C(O)CH₂-, -N(R⁷)C(O)OCH₂-, where R⁷ is as defined in claim 1.~~

4. (Original) A compound as in claim 1 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

5. (Canceled)

6. (Original) A compound of claim 1 wherein B of Formula I is

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'} halogen, cyano, and nitro; or

(ii) pyridinyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'}, halogen, cyano, and nitro ~~a substituted or unsubstituted six member aryl moiety or six member hetaryl moiety, said hetaryl moiety having 1 to 4 members selected from the group of hetaryl atoms consisting of nitrogen, oxygen and sulfur with the balance of the hetaryl moiety being carbon.~~

7. (Currently Amended) A compound of claim 1 wherein B of Formula I is phenyl, substituted with 1-3 substituents independently selected from the group consisting of nitro; or

C₁-C₁₀ alkyl,

C₁-C₁₀ alkoxy,

C₃-C₁₀ cycloalkyl,

C₆ aryl,

C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S,

substituted C₁-C₁₀ alkyl, substituted by one or more substituents independently selected from the group consisting of halogen, up to per halo, and -OR⁷, where R⁷ is H or C₁₋₁₀ alkyl;

substituted C₁-C₁₀ alkoxy, substituted by one or more substituents independently selected from the group consisting of halogen, up to per halo, and -OR⁷, where R⁷ is H or C₁₋₁₀ alkyl;

substituted C₃-C₁₀ cycloalkyl, substituted by one or more substituents independently selected from the group consisting of halogen, up to per halo, and -OR⁷, where R⁷ is H or C₁₋₁₀ alkyl;

substituted C₆ aryl, substituted by one or more substituents independently selected from the group consisting of halogen, up to per halo, and -OR⁷, where R⁷ is H or C₁₋₁₀ alkyl;

substituted C₃-C₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S, substituted by one or more substituents independently selected from the group consisting of halogen, up to per halo, and -OR⁷ where R⁷ is H or C₁₋₁₀ alkyl;

-CN; -OR⁷; CO₂R⁷; -CO(NR⁷R⁷); -C(O)R⁷; NO₂; NR⁷R⁷; NR⁷C(O)OR⁷; NR⁷C(O)R⁷, wherein R⁷ is hydrogen or C₁₋₁₀ alkyl ~~an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by a substituent selected from the group consisting of halogen and W_n wherein W and n are as defined in claim 1, a pyrimidinyl group substituted by a substituent selected from the group consisting of halogen and W_n, whereas W and n are as defined in Claim 1, or a substituted pyridyl group substituted by a substituent selected from the group consisting of halogen and W_n wherein W and n are as defined in claim 1.~~

8. (Currently Amended) A compound of claim 6 wherein B of Formula I is a ~~substituted phenyl group, a substituted pyrimidinyl group, or substituted pyridyl group~~ phenyl, substituted 1 to 3 times by 1 or more substituents selected from the group consisting of -CN, halogen, C₁-C₆ C₁₀ alkyl, C₁-C₆ C₁₀ alkoxy, -OH, up to per halo substituted C₁-C₆ C₁₀ alkyl, up to per halo substituted C₁-C₆ C₁₀ alkoxy or phenyl substituted by halogen up to per halo.

9. (Currently Amended) A compound of claim 1, wherein L is phenyl, optionally substituted by halogen up to perhalo and W_n, where n and W are as defined in claim 1, ~~the six member cyclic structure bound directly to D, is a substituted or unsubstituted 6 member aryl moiety or a substituted or unsubstituted 6 member hetaryl moiety, wherein said hetaryl moiety has 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur with the balance of said hetaryl moiety being carbon, wherein the one or more substituents are selected from the group consisting of halogen and W_n wherein W and n are as defined in claim 1.~~

10. (Currently Amended) A compound of claim 8, wherein L is
(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁-C₆ alkyl, C₁-C₆ halosubstituted alkyl and C₁-C₆ alkoxy, ~~the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.~~

11. (Currently Amended) A compound of claim 1, wherein ~~said substituted~~ cyclic moiety L¹ is

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'}, halogen, cyano and nitro; or

(ii) pyridinyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'}, halogen, cyano and nitro ~~comprises a 5 to 6 membered aryl moiety or hetaryl moiety, wherein said heteraryl moiety comprises 1 to 4 members selected from the group of heteroatoms consisting of nitrogen, oxygen and sulfur.~~

12. (Currently Amended) A compound of claim 1, wherein ~~said substituted~~ cyclic moiety L¹ is phenyl or [[,]] pyridinyl or pyrimidinyl.

13. (Currently Amended) A compound of claim 7 3, wherein said substituted cyclic moiety L^1 is phenyl or $[[,]]$ pyridinyl or pyrimidinyl.

14. (Currently Amended) A compound of claim 6, wherein said substituted cyclic moiety L^1 is phenyl or $[[,]]$ pyridinyl or pyrimidinyl.

15. (Currently Amended) A compound of claim 8, wherein said substituted cyclic moiety L^1 is phenyl or $[[,]]$ pyridinyl or pyrimidinyl.

16. (Currently Amended) A compound of claim 9, wherein said substituted cyclic moiety L^1 is phenyl or $[[,]]$ pyridinyl or pyrimidinyl.

17. (Currently Amended) A compound of claim 10, wherein said substituted cyclic moiety L^1 is phenyl or $[[,]]$ pyridinyl or pyrimidinyl.

18. (Currently Amended) A compound of claim 14, wherein M is one or more bridging groups selected from the group consisting of ~~-O- or -S- where R^7 is as defined in claim 1~~ $-O-$, $-S-$, $N(R^7)-$, $(CH_2)_m-$, $C(O)-$, $CH(OH)-$, $(CH_2)_mO-$, $(CH_2)_mS-$, $(CH_2)_mN(R^7)-$, $O(CH_2)_m-CHX^a-$, CX^a_2- , $S-(CH_2)_m-$ and $N(R^7)(CH_2)_m-$, where $m=1-3$, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

19. (Currently Amended) A compound of claim 15, wherein M is one or more bridging groups selected from the group consisting of ~~-O- or -S-~~ $-O-$, $-S-$ and, $N(R^7)-$, $(CH_2)_m-$, $C(O)-$, $CH(OH)-$, $(CH_2)_mO-$, $(CH_2)_mS-$, $(CH_2)_mN(R^7)-$, $O(CH_2)_m-CHX^a-$, CX^a_2- , $S-(CH_2)_m-$ and $N(R^7)(CH_2)_m-$, where $m=1-3$, X^a is halogen and R^7 is hydrogen or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

20. (Currently Amended) A compound of claim 16, wherein M is ~~one or more~~ bridging groups selected from the group consisting of ~~-O- or -S- -O-, -S- and, N(R⁷),~~
~~(CH₂)_m, C(O), CH(OH), (CH₂)_mO, (CH₂)_mS, (CH₂)_mN(R⁷), O(CH₂)_mCHX^a,~~
~~CX^a₂, S(CH₂)_m and N(R⁷)(CH₂)_m~~, where m=1-3, X^a is halogen and R⁷ is hydrogen or a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

21. (Currently Amended) A compound of claim 17, wherein M is ~~one or more~~ bridging groups selected from the group consisting of ~~-O- or -S- -O-, -S- and, N(R⁷),~~
~~(CH₂)_m, C(O), CH(OH), (CH₂)_mO, (CH₂)_mS, (CH₂)_mN(R⁷), O(CH₂)_mCHX^a,~~
~~CX^a₂, S(CH₂)_m and N(R⁷)(CH₂)_m~~, where m=1-3, X^a is halogen and R⁷ is hydrogen or a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen up to per halo.

22. (Currently Amended) A compound of claim 12 ~~4~~ wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

23. (Currently Amended) A compound of claim 14 ~~13~~ wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

24. (Currently Amended) A compound of claim 15 ~~18~~ wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

25. (Currently Amended) A compound of claim 16 ~~19~~ wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group

consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

26. (Currently Amended) A compound of claim 17 20 wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

27. (Original) A compound of claim 21 wherein L¹ is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C₁-C₁₀ alkyl, up to per halo substituted C₁-C₁₀ alkyl, -CN, -OH, halogen, C₁-C₁₀ alkoxy and up to per halo substituted C₁-C₁₀ alkoxy.

28.-32. (Canceled)

33. (Currently Amended) A compound of claim 13 wherein L¹ is substituted by -C(O)R_x, wherein R_x is NR_aR_b, and R_a and R_b are independently hydrogen, C₁-C₆ alkyl or C₁-C₆ alkoxy

a) ~~independently hydrogen,~~

~~a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

~~-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

b) ~~R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based~~

~~substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~e) — one of R_a or R_b is $C(O)$, a C_1 - C_5 divalent alkylene group or a substituted C_1 - C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1 - C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

34. (Currently Amended) A compound of claim 14 ~~18~~ wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 - C_6 alkyl or C_1 - C_6 alkoxy ~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

35. (Currently Amended) A compound of claim 15 ~~19~~ wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 - C_6 alkyl or C_1 - C_6 alkoxy ~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

36. (Currently Amended) A compound of claim 16 ~~20~~ wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1 - C_6 alkyl or C_1 - C_6 alkoxy ~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

37. (Currently Amended) A compound of claim ~~17~~ 24 wherein L^1 is substituted by $-C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1-C_6 alkyl or C_1-C_6 alkoxy ~~hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen.~~

38. (Currently Amended) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-NH-C(O)-NH-$,

A is a substituted moiety of up to 40 carbon atoms of the formula: $L(M-L^+)_q$;

where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D, L^+ comprises a substituted cyclic moiety having at least 5 members, M is a bridging group having at least one atom, q is an integer of from 1-3; and each cyclic structure of L and L^+ contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, and

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6 member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur,

wherein L^+ is substituted by at least one substituent selected from the group consisting of SO_2R_x , $C(O)R_x$ and $C(NR_y)R_z$, R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_z or NR_aR_b where R_a and R_b are

a) — independently hydrogen,

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and

~~carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

~~-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~b) — R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~e) — one of R_a or R_b is -C(O)-, a C₄-C₅ divalent alkylene group or a substituted C₄-C₅ divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C₄-C₅ divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~where B is substituted, L is substituted or L⁺ is additionally substituted, the substituents are selected from the group consisting of halogen, up to per halo, and W_n, where n is 0-3;~~

~~wherein each W is independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)NR⁷R⁷, -C(O)R⁷, -NO₂, -OR⁷, -SR⁷, -NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, -Q-Ar, and carbon-based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁷, -C(O)R⁷, -C(O)NR⁷R⁷, -OR⁷, -SR⁷, -NR⁷R⁷, -NO₂, -NR⁷C(O)R⁷, -NR⁷C(O)OR⁷ and halogen up to per halo; with each R⁷ independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen;~~

~~wherein Q is -O-, -S-, -N(R⁷)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -(CH₂)_mS-, -(CH₂)_mN(R⁷)-, -O(CH₂)_m-CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁷)(CH₂)_m-, where m=1-3, and X^a is halogen;~~

~~Ar is a 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per halo, and optionally substituted by Z_{n1} , wherein $n1$ is 0 to 3 and each Z is independently selected from the group consisting of CN , CO_2R^7 , $C(O)R^7$, $C(O)NR^7R^7$, NO_2 , OR^7 , SR^7 , NR^7R^7 , $NR^7C(O)OR^7$, $NR^7C(O)R^7$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents are selected from the group consisting of CN , CO_2R^7 , COR^7 , $C(O)NR^7R^7$, OR^7 , SR^7 , NO_2 , NR^7R^7 , $NR^7C(O)R^7$, and $NR^7C(O)OR^7$, with R^7 as defined above; and~~

~~wherein M is one or more bridging groups selected from the group consisting of O , S , $N(R^7)$, $(CH_2)_m$, $C(O)$, $CH(OH)$, $(CH_2)_mO$, $(CH_2)_mS$, $(CH_2)_mN(R^7)$, $O(CH_2)_m$, CHX^a , CX^a_2 , $S(CH_2)_m$ and $N(R^7)(CH_2)_m$, where $m=1-3$, X^a is halogen~~

A is of the formula: $-L-M-L^1$, wherein

L is

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl up to perhalo, C_1-C_3 alkoxy, C_1-C_3 haloalkoxy up to per haloalkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, and nitro;

L^1 comprises a substituted cyclic moiety selected from the group consisting of:

(i) phenyl, optionally substituted by 1-3 substituents which are independently methyl or halogen; or

(ii) pyridinyl, substituted with 1-3 substituents which are independently methyl or halogen;

wherein L^1 is substituted by $-C(O)R_x$,

wherein R_x is R_z or NR_aR_b and R_a and R_b are independently hydrogen,

C_1-C_{10} alkyl,

C_6 aryl,

C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S,

substituted C_{1-10} alkyl,

substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O,

substituted C₆ aryl, or

substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O,

where R_a and R_b are a substituted group, they are substituted by halogen up to per halo. and

M is selected from the group consisting of -O-, -S-, -NHC(O)- and -C(O)NH-,

q is 1- and

B is selected from the group consisting of:

(i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'} halogen, cyano, and nitro;

(ii) pyridyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R⁷, OR⁷, NR⁷R^{7'}, C(O)R⁷, C(O)OR⁷, C(O)NR⁷R^{7'}, NR⁷C(O)R^{7'}, NR⁷C(O)OR^{7'}, halogen, cyano, and nitro; and

each R⁷, R^{7'}, R_z and R_f is independently

(a) hydrogen,

(b) C₁-C₆ linear, branched, or cyclic alkyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy and hydroxy;

(c) C₁-C₆ linear or branched, alkoxy, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy and halogen;

(d) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy and halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms selected from the group consisting of O, N and S, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy and halogen,

(f) C₁-C₃ alkyl-phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy and halogen; and

(g) up to per-halo substituted C₁-C₅ linear, branched or cyclic alkyl, and where not per-halo substituted, optionally substituted with 1-3 substituents independently selected from the group consisting of C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy and hydroxy.

39. (Currently Amended) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: $L(M L^+)_q$,

where L is a substituted or unsubstituted phenyl or moiety bound directly to D, L^+ comprises a substituted phenyl, or pyrimidinyl moiety, M is bridging group having at least one atom, q is an integer of from 1-3; and

B is a substituted or unsubstituted phenyl or group bound directly to D,

wherein L^+ is substituted by at least one substituent selected from the group consisting of SO_2R_x , $C(O)R_x$ and $C(NR_y)R_z$,

R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo, and;

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_z or NR_aR_b where R_a and R_b are

a) — independently hydrogen;

a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and

~~carbon-based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or~~

~~-OSi(R_f)₃ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~b) — R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or~~

~~e) — one of R_a or R_b is C(O)—, a C₁-C₅-divalent alkylene group or a substituted C₁-C₅-divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C₁-C₅-divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;~~

~~where B is substituted, L is substituted or L[†] is additionally substituted, the substituents are selected from the group consisting of halogen, up to per halo, and W_n, where n is 0-3;~~

~~wherein each W is independently selected from the group consisting of CN, CO₂R⁷, C(O)NR⁷R⁷, C(O)R⁷, NO₂, OR⁷, SR⁷, NR⁷R⁷, NR⁷C(O)OR⁷, NR⁷C(O)R⁷, Q Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the group consisting of CN, CO₂R⁷, C(O)R⁷, C(O)NR⁷R⁷, OR⁷, SR⁷, NR⁷R⁷, NO₂, NR⁷C(O)R⁷, NR⁷C(O)OR⁷ and halogen up to per halo; with each R⁷ independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen;~~

wherein Q is ~~O, S, N(R⁷), (CH₂)_m, C(O), CH(OH), (CH₂)_mO, (CH₂)_mS, (CH₂)_mN(R⁷), O(CH₂)_mCHX^a, CX^a₂, S(CH₂)_m and N(R⁷)(CH₂)_m~~, where m=1-3, and X^a is halogen;

Ar is a ~~5 or 6 member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per halo, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of CN, CO₂R⁷, C(O)R⁷, C(O)NR⁷R⁷, NO₂, OR⁷, SR⁷, NR⁷R⁷, NR⁷C(O)OR⁷, NR⁷C(O)R⁷, and a carbon-based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of CN, CO₂R⁷, COR⁷, C(O)NR⁷R⁷, OR⁷, SR⁷, NO₂, NR⁷R⁷, NR⁷C(O)R⁷, and NR⁷C(O)OR⁷~~; and wherein M is one or more bridging groups selected from the group consisting of ~~O, S, N(R⁷), (CH₂)_m, C(O), CH(OH), (CH₂)_mO, (CH₂)_mS, (CH₂)_mN(R⁷), O(CH₂)_mCHX^a, CX^a₂, S(CH₂)_m and N(R⁷)(CH₂)_m~~, where m=1-3, X^a is halogen.

A is of the formula:



where L is

M is

and l are each independently integers of from,

~~O, S, N(R⁷), (CH₂)_m, C(O), CH(OH), (CH₂)_mO, (CH₂)_mS, (CH₂)_mN(R⁷), O(CH₂)_mCHX^a, CX^a₂, S(CH₂)_m and N(R⁷)(CH₂)_m~~, where m=1-3,

and

B is

L is phenyl,

M is -O-,

L¹ is pyridinyl substituted by -C(O)R_x

wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen,

C₁-C₁₀ alkyl,

C₁-C₁₀ alkoxy,

C₃₋₁₀ cycloalkyl,

C₆ aryl,

C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from O, N and S,

substituted C₁₋₁₀ alkyl,

substituted C₁₋₁₀ alkoxy,

substituted C₃₋₁₀ cycloalkyl, having 0-3 heteroatoms selected from N, S and O,

substituted C₆ aryl, or

substituted C₃₋₁₂ hetaryl having 1-3 heteroatoms selected from N, S and O,

where R_a and R_b are a substituted group, they are substituted by

halogen up to per halo, and

B is a phenyl group substituted by substituents selected from the group consisting of hydrogen up to per halo, and W where n is 0-3, and each W is independently selected from the group consisting of

C₁-C₁₀ alkyl,

C₁-C₁₀ alkoxy,

C₃-C₁₀ cycloalkyl,

C₆ aryl,

C₃-C₁₂ heteroaryl having 1-3 heteroatoms selected from O, N and S,

substituted C₁-C₁₀ alkyl, substituted by one or more substituents independently selected from the group consisting of -OR⁷ and halogen up to per halo, wherein R⁷ is hydrogen or C₁-C₁₀ alkyl;

substituted C₁-C₁₀ alkoxy, substituted by one or more substituents independently selected from the group consisting of -OR⁷ and halogen up to per halo, wherein R⁷ is hydrogen or C₁-C₁₀ alkyl;

substituted C₃-C₁₀ cycloalkyl, substituted by one or more substituents independently selected from the group consisting of -OR⁷ and halogen up to per halo, wherein R⁷ is hydrogen or C₁-C₁₀ alkyl;

substituted C₆ aryl, substituted by one or more substituents independently selected from the group consisting of -OR⁷ and halogen up to per halo, wherein R⁷ is hydrogen or C₁-C₁₀ alkyl;

substituted C₃-C₁₂ heteroaryl having 1-3 heteroatoms selected from O, N and S, substituted by one or more substituents independently selected from the group consisting of -OR⁷ and halogen up to per halo, wherein R⁷ is hydrogen or C₁-C₁₀ alkyl;

-CN,

-CO₂R⁷,

-C(O)NR⁷R⁷,

-C(O)R⁷,

-NO₂,

-OR⁷,

-NR⁷R⁷

-NR⁷C(O)OR⁷ and

-NR⁷C(O)R⁷, wherein R⁷ is hydrogen, or C₁-C₁₀ alkyl.

40. (Original) A compound as in claim 38 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

41. (Canceled)

42. (Original) A compound as in claim 39 wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by-OH.

43. (Canceled)

44. (Currently Amended) A compound as in claim 38 wherein substituents for B and L and additional substituents for L⁺, are selected from the group consisting of C₁-C₆-C₁₀ alkyl up to per halo substituted C₁-C₆-C₁₀ alkyl, CN, OH, halogen, C₁-C₆-C₁₀ alkoxy and up to per halo substituted C₁-C₆-C₁₀ alkoxy.

45. (Currently Amended) A compound as in claim 39 wherein substituents for B and L and additional substituents for L⁺, are selected from the group consisting of C₁-C₆-C₁₀

alkyl up to per halo substituted C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy and up to per halo substituted C_1-C_{10} alkoxy.

46. (Canceled)

47. (Canceled)

48. (Currently Amended) A compound of claim 46 38 wherein R_x is NR_aR_b and R_a and R_b are independently R_z .

49. (Currently Amended) A compound of claim 47 39 wherein R_x is NR_aR_b and R_a and R_b are independently R_z .

50. (Currently Amended) A compound of claim 1 which is a pharmaceutically acceptable salt of a compound of formula I of claim 1 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

~~selected from the group consisting of~~

~~a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid,~~

~~fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and~~

~~b) — acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.~~

51. (Currently Amended) A compound of ~~claim 2~~ which is a pharmaceutically acceptable salt of a compound of claim 61 which is formula I selected from the group consisting of

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

~~selected from the group consisting of~~

~~a) — basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and~~

~~b) — acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.~~

52. (Canceled)

53. (Currently Amended) A ~~compound of claim 38 which is a pharmaceutically acceptable salt of a compound of formula I~~ claim 38 which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

~~selected from the group consisting of~~

a) ~~basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and~~

b) ~~acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.~~

54. (Currently Amended) A ~~compound of claim 39 which is a pharmaceutically acceptable salt of a compound of formula I of claim 39~~ which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid,

trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

~~selected from the group consisting of~~

~~a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and~~

~~b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.~~

55. (Original) A pharmaceutical composition for the treatment of a cancerous cell growth mediated by raf kinase comprising a compound of claim 1 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

56. (Canceled)

57. (Canceled)

58. (Original) A pharmaceutical composition of claim 55 wherein the compound of formula I is that defined in claim 38.

59. (Original) A pharmaceutical composition of claim 55 wherein the compound of formula I is that defined in claim 39.

60. (Canceled)

61. (Original) A compound selected from the group consisting of
the 3-*tert* butyl phenyl ureas:

N-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and
N-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl) urea;

the 5-*tert*-butyl-2-methoxyphenyl ureas:

N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisindolin-5-yloxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisindolin-5-yloxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;

the 2-methoxy-5-trifluoromethylphenyl ureas:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

the 4-chloro-3-(trifluoromethyl)phenyl ureas:

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

the 4-bromo-3-(trifluoromethyl)phenyl ureas:

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.

62. (Original) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 1.

63. (Canceled)

64. (Original) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 38.

65. (Original) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of Formula I of claim 39.

66. (Canceled)

67. (Original) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound selected from the group consisting of the 3-*tert* butyl phenyl ureas:

N-(3-*tert*-butylphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and
N-(3-*tert*-butylphenyl)-*N'*-(4-(4-acetylphenoxy)phenyl) urea;

the 5-*tert*-butyl-2-methoxyphenyl ureas:

N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1,3-dioxoisindolin-5-yl)oxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(1-oxoisindolin-5-yl)oxy)phenyl) urea,
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea and
N-(5-*tert*-butyl-2-methoxyphenyl)-*N'*-(4-(3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea;

the 2-methoxy-5-(trifluoromethyl)phenyl ureas:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and
N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea;

the 4-chloro-3-(trifluoromethyl)phenyl ureas:

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-carbamoyl-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea and
N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

the 4-~~romo~~bromo-3-(trifluoromethyl)phenyl ureas:

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridylthio)phenyl) urea,
N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(4-bromo-3-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea; and

the 2-methoxy-4-chloro-5-(trifluoromethyl)phenyl ureas:

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(2-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea and

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-chloro-4-(2-(*N*-methylcarbamoyl)(4-pyridyloxy))phenyl) urea.

68. (New) A compound of claim 1 wherein the optional substituents on L¹ are selected from the group consisting of methyl, trifluoromethyl, methoxy, Cl and F.

69. (New) A compound of claim 1 wherein the optional substituents of B and L are independently selected from the group consisting of methyl, trifluoromethyl, ethyl, n-propyl, n-butyl, n-pentyl, *tert*-butyl, *sec*-butyl, isobutyl, methoxy, ethoxy, propoxy, Cl, and F.

70. (New) A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of formula I of claim 1 or a pharmaceutically acceptable salt of a compound of formula I and a physiologically acceptable carrier.

71. (New) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of the formula:



wherein L is selected from the group consisting of:

(i) phenyl, optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₅ alkyl, C₁-C₅ alkyl substituted by halogen and C₁-C₅ alkoxy;

or

(ii) pyridinyl optionally substituted with substituents selected from the group consisting of halogen, C₁-C₅ alkyl, C₁-C₅ alkyl substituted by halogen and C₁-C₅ alkoxy;

L¹ comprises a substituted cyclic moiety selected from the group consisting of:


(i) phenyl, substituted with a substituent selected from the group consisting of -C(O)R^c and -C(O)NR^aR^b

and optionally substituted with one or two substituents selected from the group consisting of R⁷, OR⁷ and halogen wherein R⁷ is hydrogen, C₁-C₅ alkyl or C₁-C₅ alkyl substituted by halogen, and


(ii) pyridinyl, substituted with a substituent selected from the group consisting of C(O)R^c and -C(O)NR^aR^b

and optionally substituted with one or two substituents selected from the group consisting of R⁷, OR⁷ and halogen, wherein R⁷ is hydrogen, C₁-C₅ alkyl or C₁-C₅ alkyl substituted by halogen,

or (iii)



or



R⁸ is hydrogen or C₁-C₅ alkyl,

R^c is a) hydrogen

b) C₁-C₅ alkyl, optionally substituted by halogen, hydroxy or C₁-C₃ alkoxy,

c) phenyl, optionally substituted by halogen, hydroxy, C₁-C₅ alkyl, C₁-C₃ alkoxy or CF₃

d) pyridinyl, optionally substituted by halogen, hydroxy, C₁-C₅ alkyl, C₁-C₄ alkoxy or CF₃;

- e) piperiazinyl, optionally substituted by halogen, hydroxy, C₁-C₅ alkyl, C₁-C₄ alkoxy, CF₃ or phenyl, optionally substituted by halogen, -C(O)CH₃,

wherein R^a and R^b independently are

- a) hydrogen,
b) C₁-C₅ alkyl, optionally substituted by CF₃, morpholinyl, C₁-C₃ alkoxy, piperidinyl, furyl, C₁-C₃ alkylpyrrolidinyl, -NH-(phenyl), hydroxy, halogen, -OSi(C₁-C₅ alkyl)₃ or di(C₁-C₄ alkyl)amino,
c) phenyl, optionally substituted by halogen, di(C₁-C₄ alkyl)amino, morpholinyl, -piperazine(phenyl), optionally substituted by halogen or -C(O)CH₃; piperazine(pyridyl), hydroxy, C₁-C₅ alkyl, CF₃, C₁-C₃ alkoxy or -NH-(phenyl),
d) pyridinyl, optionally substituted by -C₁-C₄ alkoxy, -piperazine(phenyl), optionally substituted by halogen or -C(O)CH₃, piperazine(pyridyl), hydroxy, halogen, C₁-C₅ alkyl, CF₃, di(C₁-C₄ alkyl)amino, morpholinyl, or -NH-(phenyl),

M is one or two bridging groups selected from the group consisting of

-O-, -S-, -C(O)-, -NH-, -CH₂-, -CH(OH)-, -CHX^a- and -CX^a₂-, where X^a is halogen;

B is selected from the group consisting of:

- (i) phenyl, optionally substituted with substituents independently selected from the group consisting of
a) halogen;
b) C₁-C₅ alkyl, optionally substituted by halogen or -OR⁷ wherein R⁷ is hydrogen or C₁-C₅ alkyl;
c) C₁-C₄ alkoxy, optionally substituted by halogen;
d) phenyl or -O-phenyl, optionally substituted by -C(O)NHCH₃, C₁-C₅ alkyl, halogen or -OR⁷ wherein R⁷ is hydrogen or C₁-C₅ alkyl; or
e) pyrrolyl or pyridinyl, optionally substituted by C₁-C₅ alkyl, halogen or -OR⁷ wherein R⁷ is hydrogen or C₁-C₅ alkyl;

or

- (ii) naphthylene optionally substituted with substituents independently selected from the group consisting of

- a) halogen;
- b) C₁-C₅ alkyl, optionally substituted by halogen or -OR⁷ wherein R⁷ is hydrogen or C₁-C₅ alkyl; or
- c) C₁-C₄ alkoxy, optionally substituted by halogen.

72. (New) A pharmaceutical composition for the treatment of a cancerous cell growth as in claim 70 wherein the pharmaceutically acceptable salt is

- a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or
- b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

73. (New) A compound of the formula



or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-

B is phenyl substituted by 1-3 substituents,

A is -L-M-L¹, wherein

L is optionally substituted phenyl,

M is -O- or -S-, and

L¹ pyridinyl substituted by C(O)R^aR^b, wherein R^a and R^b are each independently H, C₁-C₁₀ alkyl or substituted C₁-C₁₀ alkyl.

74. (New) A compound as in claim 73 wherein

B is phenyl substituted by 1-3 substituents selected from halogen, C₁-C₁₀ alkoxy, C₁-C₁₀ alkyl, and C₁-C₁₀ alkyl substituted by halogen up to per-halo, L is unsubstituted phenyl

and R^a and R^b are each independently H, C₁-C₁₀ alkyl or substituted C₁-C₁₀ alkyl substituted by OH, -N(CH₃)₂, morpholino, -OCH₃, furan, piperidine, pyridine or -OSi(C₃H₇)₃.

75. (New) A compound as in claim 1 wherein B, L and L¹ follow one of the following of combinations:

B= phenyl, L=phenyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B= phenyl, L=pyridinyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B=phenyl, L = naphthyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B=pyridinyl, L= phenyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B=pyridinyl, L= pyridinyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B =isoquinolinyl, L= phenyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B= isoquinolinyl, L= pyridinyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B= quinolinyl, L= phenyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B= quinolinyl, L= pyridinyl and L¹ is phenyl, pyridinyl, quinolinyl or isoquinolinyl.

76. (New) A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of claim 1 or a pharmaceutically acceptable salt of a compound of formula I and a physiologically acceptable carrier.

77. (New) A pharmaceutical composition for the treatment of a cancerous cell growth as in claim 76 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

78. (New) A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$,

A is a substituted moiety of the formula:

$-\text{L}-\text{M}-\text{L}^1$,

wherein

L is selected from the group consisting of phenyl and pyridinyl;

L^1 is selected from the group consisting of phenyl and pyridinyl;

and

M is selected from the group consisting of $-\text{O}-$, $-\text{S}-$ and $-\text{NHCO}-$;

wherein L^1 is substituted by $-\text{C}(\text{O})\text{NR}_a\text{R}_b$,

wherein $-\text{R}_a$ and $-\text{R}_b$ are independently:

hydrogen,

$\text{C}_1\text{-C}_{10}$ alkyl,

$\text{C}_6\text{-C}_{12}$ aryl,

C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S, substituted C_{1-10} alkyl,

substituted C_{6-12} aryl,

substituted C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O,

$-\text{C}_2\text{H}_4\text{OSi}(\text{Pr-i})_3$,

-phenylpiperazine(pyridyl), and

$-\text{C}_2\text{H}_4\text{NH}(\text{phenyl})$,

where R_a and R_b are a substituted group, they are substituted by

i) halogen up to per halo,

ii) hydroxy,

iii) C_{1-10} alkyl,

iv) C_{1-10} alkoxy,

v) $-\text{N}(\text{CH}_3)_2$ and

vi) C_{3-12} cycloalkyl, having 1-3 heteroatoms selected from O, N and S, and

B is selected from the group consisting of:

(i) phenyl and naphthyl, and wherein B is optionally substituted with halogen up to perhalo, and optionally substituted with 1-3 substituents independently selected from the group consisting of

OR⁷,

C₁-C₁₀ alkyl, up to per-halosubstituted C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy,

phenyl,

C₃-C₁₂ heteroaryl having 1-3 heteroatoms selected from the group consisting of O, N and S,

-O-phenyl-C(O)NHCH₃,

and

2,5-dimethyl pyrrolyl

wherein each R⁷ is independently

(a) C₁-C₁₀ alkyl,

and

(b) phenyl,

wherein the cyclic structures of B and L bound directly to D are not substituted in the ortho position by -OH.